Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2023 | Chronic Inflammatory Bowel Disease | Research

Complementary and alternative medicine mention and recommendations in inflammatory bowel disease guidelines: systematic review and assessment using AGREE II

Authors: Jeremy Y. Ng, Henry Liu, Michelle Chenghuazou Wang

Published in: BMC Complementary Medicine and Therapies | Issue 1/2023

Abstract

Background

Many patients with inflammatory bowel disease (IBD) use complementary and alternative medicine (CAM) for disease management. There is, however, a communication gap between patients and healthcare professionals regarding CAM use, where patients are hesitant to disclose CAM use to providers. The purpose of this study was to identify the quantity and assess the quality of CAM recommendations in IBD clinical practice guidelines (CPGs) using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument.

Methods

MEDLINE, EMBASE, and CINAHL were systematically searched from 2011 to 2022 to find CPGs for the treatment and/or management of IBD. The Guidelines International Network (GIN) and National Center for Complementary and Integrative Health (NCCIH) websites were also searched. Eligible CPGs were assessed using the AGREE II instrument.

Results

Nineteen CPGs made CAM recommendations for IBD and were included in this review. Average scaled domain percentages of CPGs were as follows (overall CPG, CAM section): scope and purpose (91.5%, 91.5%), clarity of presentation (90.3%, 64.0%), editorial independence (57.0%, 57.0%), stakeholder involvement (56.7%, 27.8%), rigour of development (54.7%, 45.9%), and applicability (14.6%, 2.1%).

Conclusions

The majority of CPGs with CAM recommendations were of low quality and their CAM sections scored substantially lower relative to other therapies in the overall CPG. In future updates, CPGs with low scaled-domain percentages could be improved in accordance with AGREE II and other guideline development resources. Further research investigating how CAM therapies can best be incorporated into IBD CPGs is warranted.

Available only for authorised users

Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205–17. https://doi.org/10.1038/nrgastro.2015.34.

Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12(2):113–22. https://doi.org/10.25122/jml-2018-0075.CrossRefPubMedPubMedCentral

Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–94. https://doi.org/10.1053/j.gastro.2011.01.055.

Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterol 2012;142(1):46–54e42. doi: https://doi.org/10.1053/j.gastro.2011.10.001.

Jones JL, Nguyen GC, Benchimol EI, Bernstein CN, Bitton A, Kaplan GG, Murthy SK, Lee K, Cooke-Lauder J, Otley AR. The impact of inflammatory bowel disease in Canada 2018: quality of life. Journal of the Canadian Association of Gastroenterology. 2019;2(Supplement_1):S42-8. doi: https://doi.org/10.1093/jcag/gwy048.

Ng JY, Chauhan U, Armstrong D, Marshall J, Tse F, Moayyedi P, Reinisch W, Halder S. A comparison of the prevalence of anxiety and depression between uncomplicated and complex IBD patient groups. Gastroenterology Nursing. 2018;41(5):427 – 35. doi: https://doi.org/10.1097/SGA.0000000000000338.

Szigethy EM, Allen JI, Reiss M, Cohen W, Perera LP, Brillstein L, Cross RK, Schwartz DA, Kosinski LR, Colton JB, LaRusso E. White paper AGA: the impact of mental and psychosocial factors on the care of patients with inflammatory bowel disease. Clinical Gastroenterology and Hepatology. 2017;15(7):986 – 97. doi: https://doi.org/10.1016/j.cgh.2017.02.037.

Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720–7. https://doi.org/10.1038/nrgastro.2015.150.

What is inflammatory bowel disease (IBD). ? | IBD. Centers for Disease Control and Prevention. 2022 [cited 2022 Jun 1]. Available from: https://www.cdc.gov/ibd/what-is-IBD.htm.

10.

Cheifetz AS, Gianotti R, Luber R, Gibson PR. Complementary and alternative Medicines used by patients with inflammatory Bowel Diseases. Gastroenterology. 2017;152(2):415–429e15. https://doi.org/10.1053/j.gastro.2016.10.004.

11.

Mishra R, Dhawan P, Srivastava AS, Singh AB. Inflammatory bowel disease: therapeutic limitations and prospective of the stem cell therapy. World J Stem Cells. 2020;12(10):1050–66. https://doi.org/10.4252/wjsc.v12.i10.1050.CrossRefPubMedPubMedCentral

12.

Peyrin-Biroulet L, Lémann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33(8):870–9. https://doi.org/10.1111/j.1365-2036.2011.04599.x.CrossRefPubMed

13.

Vangeli E, Bakhshi S, Baker A, et al. A systematic review of factors Associated with Non-Adherence to Treatment for Immune-Mediated inflammatory Diseases. Adv Ther. 2015;32(11):983–1028. https://doi.org/10.1007/s12325-015-0256-7.CrossRefPubMedPubMedCentral

14.

Bauer N, Kairey L, Schlee C, Uecker C, Öznur Ö, Langhorst J. Use of complementary and alternative medicine (CAM) in patients with inflammatory bowel disease (IBD): results from a german nationwide survey of 2019 compared to a previous survey of 2002. Scand J Gastroenterol. 2022;57(10):1209–15. https://doi.org/10.1080/00365521.2022.2078667.CrossRefPubMed

15.

Mountifield R, Andrews JM, Mikocka-Walus A, Bampton P. Doctor communication quality and friends’ attitudes influence complementary medicine use in inflammatory bowel disease. World J Gastroenterol. 2015;21(12):3663–70. https://doi.org/10.3748/wjg.v21.i12.3663.CrossRefPubMedPubMedCentral

16.

Weizman AV, Ahn E, Thanabalan R, et al. Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35(3):342–9. https://doi.org/10.1111/j.1365-2036.2011.04956.x.CrossRefPubMed

17.

Ng JY, Boon HS, Thompson AK, Whitehead CR. Making sense of “alternative”, “complementary”, “unconventional” and “integrative” medicine: exploring the terms and meanings through a textual analysis. BMC Complement Altern Med. 2016;16(1):134. https://doi.org/10.1186/s12906-016-1111-3.

18.

Complementary alternative, or Integrative Health. : What’s in a name?. National Center for Complementary and Integrative Health. U.S. Department of Health and Human Services; 2021 [cited 2022 Jun 8]. Available from: https://www.nccih.nih.gov/health/complementary-alternative-or-integrative-health-whats-in-a-name.

19.

Lin SC, Cheifetz AS. The use of complementary and alternative medicine in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2018;14(7):415–25.

20.

Koning M, Ailabouni R, Gearry RB, Frampton CMA, Barclay ML. Use and predictors of oral complementary and alternative medicine by patients with inflammatory bowel disease: a population-based, case-control study. Inflamm Bowel Dis 2013;19(4):767–78. doi: https://doi.org/10.1097/mib.0b013e31827f27c8.

21.

Langhorst J, Wulfert H, Lauche R, Klose P, Cramer H, Dobos GJ et al. Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. J Crohns Colitis 2015;9(1):86–106. doi: https://doi.org/10.1093/ecco-jcc/jju007.

22.

Yanai H, Salomon N, Lahat A. Complementary therapies in Inflammatory Bowel Diseases. Curr Gastroenterol Rep. 2016;18(12):62. https://doi.org/10.1007/s11894-016-0537-6.

23.

Nguyen GC, Croitoru K, Silverberg MS, Steinhart AH, Weizman AV. Use of complementary and alternative medicine for inflammatory bowel disease is Associated with worse adherence to conventional therapy: the COMPLIANT study. Inflamm Bowel Dis. 2016;22(6):1412–7. https://doi.org/10.1097/mib.0000000000000773.

24.

Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2010;105(10):2218–27. https://doi.org/10.1038/ajg.2010.218.

25.

Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68(Suppl 3):s1–106. doi: https://doi.org/10.1136/gutjnl-2019-318484.

26.

Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999;20(7182):527–30. https://doi.org/10.1136/bmj.318.7182.527.

27.

What are practice guidelines?. AGREE Enterprise [cited 2023 May 6]. Available from: https://www.agreetrust.org/practice-guidelines/.

28.

Patel SJ, Kemper KJ, Kitzmiller JP. Physician perspectives on education, training, and implementation of complementary and alternative medicine. Adv Med Educ Pract. 2017;8:499–503. https://doi.org/10.2147/amep.s138572.CrossRefPubMedPubMedCentral

29.

Higgins JPT, Green S, editors. Cochrane Handbook for systematic reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011.

30.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst reviews. 2021;10(1):1–1. https://doi.org/10.1186/s13643-021-01626-4.

31.

Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Grimshaw J, Hanna SE, Littlejohns P. AGREE II: advancing guideline development, reporting and evaluation in health care. Can Med Assoc J. 2010;182(18):E839–42. https://doi.org/10.1503/cmaj.090449.CrossRef

32.

Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Hanna SE, Makarski J. Development of the AGREE II, part 1: performance, usefulness and areas for improvement. Cmaj 2010 Jul 13;182(10):1045–52. doi: https://doi.org/10.1503/cmaj.091714.

33.

Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Hanna SE, Makarski J. Development of the AGREE II, part 2: assessment of validity of items and tools to support application. Cmaj 2010;182(10):E472–8. doi: https://doi.org/10.1503/cmaj.091716.

34.

Guidelines International Network. Guidelines International Network; date unknown [cited 2022 Jun 3]. Available from: https://www.g-i-n.net/.

35.

Clinical Practice Guidelines. National Center for Complementary and Integrative Health; date unknown [cited 2022 Jun 3]. Available from: https://www.nccih.nih.gov/health/providers/clinicalpractice.

36.

Macaluso FS, Orlando A, Papi C, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, Fiorino G, Fantini MC, Caprioli F. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Digestive and Liver Disease. 2022;54(4):440 – 51. doi: https://doi.org/10.1016/j.dld.2022.01.127.

37.

Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, Bachmann O, Bettenworth D, Chaparro M, Czuber-Dochan W, Eder P. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohn’s Colitis 2022;16(1):2–17. doi: https://doi.org/10.1093/ecco-jcc/jjab178.

38.

Spinelli A, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, Bachmann O, Bettenworth D, Chaparro M, Czuber-Dochan W, Eder P. ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment. J Crohn’s Colitis. 2022;16(2):179–89. https://doi.org/10.1093/ecco-jcc/jjab177.

39.

De Simone B, Davies J, Chouillard E, Di Saverio S, Hoentjen F, Tarasconi A, Sartelli M, Biffl WL, Ansaloni L, Coccolini F, Chiarugi M. WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting. World J Emerg Surg 2021;16(1):1–27. doi: https://doi.org/10.1186/s13017-021-00362-3.

40.

Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, Terdiman JP, Sultan S, Cohen BL, Chachu K, Day L. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology. 2021;160(7):2496 – 508. doi: https://doi.org/10.1053/j.gastro.2021.04.022.

41.

Holubar SD, Lightner AL, Poylin V, Vogel JD, Gaertner W, Davis B, Davis KG, Mahadevan U, Shah SA, Kane SV, Steele SR. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the surgical management of ulcerative colitis. Diseases of the Colon & Rectum. 2021;64(7):783–804. doi: https://doi.org/10.1097/DCR.0000000000002037.

42.

Łodyga M, Eder P, Gawron-Kiszka M, Dobrowolska A, Gonciarz M, Hartleb M, Kłopocka M, Małecka-Wojciesko E, Radwan P, Reguła J, Zagórowicz E. Guidelines for the management of patients with Crohn’s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National consultant in Gastroenterology. Gastroenterol Review/PrzeglÄ d Gastroenterologiczny. 2021;16(1). https://doi.org/10.5114/pg.2021.110914.

43.

Miehlke S, Guagnozzi D, Zabana Y, Tontini GE, Kanstrup Fiehn AM, Wildt S, Bohr J, Bonderup O, Bouma G, D’Amato M, Heiberg Engel PJ. European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations. UEG J. 2021;9(1):13–37. https://doi.org/10.1177/2050640620951905.

44.

Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56(6):489–526. https://doi.org/10.1007/s00535-021-01784-1.

45.

Adamina M, Bonovas S, Raine T, Spinelli A, Warusavitarne J, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P. ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment. Journal of Crohn’s and Colitis. 2020;14(2):155 – 68. doi: https://doi.org/10.1093/ecco-jcc/jjz187.

46.

Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S, Chachu K, Day L, Lebwohl B, Muniraj T, Patel A. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450-61. doi: https://doi.org/10.1053/j.gastro.2020.01.006.

47.

Levine A, Rhodes JM, Lindsay JO, Abreu MT, Kamm MA, Gibson PR, Gasche C, Silverberg MS, Mahadevan U, Boneh RS, Wine E. Dietary guidance from the international organization for the study of inflammatory bowel diseases. Clinical Gastroenterology and Hepatology. 2020;18(6):1381-92. doi: https://doi.org/10.1053/j.gastro.2020.01.006.

48.

Colombel JF, Shin A, Gibson PR. AGA clinical practice update on functional gastrointestinal symptoms in patients with inflammatory bowel disease: Expert Review. Clin Gastroenterol Hepatol. 2019;17(3):380–390e1. https://doi.org/10.1016/j.cgh.2018.08.001.CrossRefPubMed

49.

Lightner AL, Vogel JD, Carmichael JC, Keller DS, Shah SA, Mahadevan U, Kane SV, Paquette IM, Steele SR, Feingold DL. The American society of colon and rectal surgeons clinical practice guidelines for the surgical management of Crohn’s disease. Diseases of the Colon & Rectum. 2020;63(8):1028-52. doi: https://doi.org/10.1097/DCR.0000000000001716.

50.

Shen B, Kochhar G, Navaneethan U, Farraye FA, Schwartz DA, Iacucci M, Bernstein CN, Dryden G, Cross R, Bruining DH, Kobayashi T. Practical guidelines on endoscopic treatment for Crohn’s disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. The Lancet Gastroenterology & Hepatology. 2020;5(4):393–405. doi: https://doi.org/10.1016/S2468-1253(19)30366-8.

51.

Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. Journal of Crohn’s and Colitis. 2020;14(1):4–22. doi: https://doi.org/10.1093/ecco-jcc/jjz180.

52.

Bonnaud G, Bouhnik Y, Hagège H, Hebuterne X, Pariente B, Roblin X, Peyrin-Biroulet L. Monitoring of inflammatory bowel disease in 2019: a french consensus for clinical practice. Dig Liver Dis. 2020;52(7):704–20. https://doi.org/10.1016/j.dld.2020.03.033.CrossRefPubMed

53.

Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK, Crockett S, Feuerstein J, Flamm S, Inadomi J, Ko C. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019;156(3):748 – 64. doi: https://doi.org/10.1053/j.gastro.2018.12.009.

54.

Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengiesser K, Kienle P, Langhorst J, Luegering A, Schreiber S. Updated S3-Guideline ulcerative colitis. German society for digestive and metabolic diseases (DGVS). Z für Gastroenterologie 2019;57(02):162–241. doi: https://doi.org/10.1055/a-0651-8174.

55.

Ulcerative colitis: management: NICE guideline [NG130], National Institute for Health and Care Excellence. ; 2019 [cited 2022 Aug 24]. Available from: https://www.nice.org.uk/guidance/ng130.

56.

Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B. Canadian Association of Gastroenterology clinical practice guideline for the management of luminal Crohn’s disease. Clin Gastroenterol Hepatol 2019;17(9):1680–713. doi: https://doi.org/10.1016/j.cgh.2019.02.043.

57.

Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B. Canadian Association of Gastroenterology clinical practice guideline for the management of luminal Crohn’s disease. Journal of the Canadian Association of Gastroenterology. 2019;2(3):e1-34. doi: https://doi.org/10.1093/jcag/gwz019.

58.

Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Official journal of the American College of Gastroenterology ACG. 2019;114(3):384–413. oi: https://doi.org/10.14309/ajg.0000000000000152.

59.

Sood A, Ahuja V, Kedia S, Midha V, Mahajan R, Mehta V, Sudhakar R, Singh A, Kumar A, Puri AS, Tantry BV. Diet and inflammatory bowel disease: the asian Working Group guidelines. Indian J Gastroenterol. 2019;38(3):220–46. https://doi.org/10.1007/s12664-019-00976-1.

60.

Steinhart AH, Panaccione R, Targownik L, Bressler B, Khanna R, Marshall JK, Afif W, Bernstein CN, Bitton A, Borgaonkar M, Chauhan U. Clinical practice guideline for the medical management of perianal fistulizing Crohn’s disease: the Toronto consensus. Inflammatory bowel diseases. 2019;25(1):1–3. doi: https://doi.org/10.1093/ibd/izy247.

61.

Teixeira FV, Vilela EG, Damião AO, Vieira A, Albuquerque IC, Parente JM, Chebli JM, Ambrogini O, Hossne RS, Miszputen SJ. Ulcerative colitis-treatment with biologicals. Revista da Associação Médica Brasileira. 2019;65:547 – 53. doi: https://doi.org/10.1590/1806-9282.65.4.547.

62.

Zaltman C, Amarante H, Machado MB, Costa MH, Flores C, Leal RF, Genoile S, Zeroncio M. Crohn’s disease-treatment with biological medication. Revista da Associação Médica Brasileira. 2019;65:554 – 67. doi: https://doi.org/10.1590/1806-9282.65.4.554.

63.

Bemelman WA, Warusavitarne J, Sampietro GM, Serclova Z, Zmora O, de Luglio G Buck, van Overstraeten A, Burke JP, Buskens CJ, Colombo F, Dias JA. ECCO-ESCP consensus on surgery for Crohn’s disease. Journal of Crohn’s and Colitis. 2018;12(1):1–6. doi: https://doi.org/10.1093/ecco-jcc/jjx061.

64.

Brown SR, Fearnhead NS, Faiz OD, Abercrombie JF, Acheson AG, Arnott RG, Clark SK, Clifford S, Davies RJ, Davies MM, Douie WJ. The Association of Coloproctology of Great Britain and Ireland consensus guidelines in surgery for inflammatory bowel disease. Colorectal Dis. 2018;20:3–117. https://doi.org/10.1111/codi.14448.

65.

Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Official journal of the American College of Gastroenterology| ACG. 2018;113(4):481–517. doi: https://doi.org/10.1038/ajg.2018.27.

66.

Forbes A, Escher J, Hébuterne X, Kłęk S, Krznaric Z, Schneider S, Shamir R, Stardelova K, Wierdsma N, Wiskin AE, Bischoff SC. ESPEN guideline: Clinical nutrition in inflammatory bowel disease. Clinical Nutrition. 2017;36(2):321 – 47. doi: https://doi.org/10.1016/j.clnu.2016.12.027.

67.

Gionchetti P, Rizzello F, Annese V, Armuzzi A, Biancone L, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’Incà R. Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. Digestive and Liver Disease. 2017;49(6):604 – 17. doi: https://doi.org/10.1016/j.dld.2017.01.161.

68.

Nguyen GC, Loftus EV, Hirano I, Falck–Ytter Y, Singh S, Sultan S, Flamm SL, Lim JK, Rubenstein JH, Smalley WE, Stollman N. American Gastroenterological Association Institute guideline on the management of Crohn’s disease after surgical resection. Gastroenterology. 2017;152(1):271-5. doi: https://doi.org/10.1053/j.gastro.2016.10.038.

69.

Bernstein CN, Eliakim A, Fedail S, Fried M, Gearry R, Goh KL, Hamid S, Khan AG, Khalif I, Ng SC, Ouyang Q. World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015. J Clin Gastroenterol. 2016;50(10):803–18. https://doi.org/10.1097/MCG.0000000000000660.CrossRefPubMed

70.

Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, Burisch J, De Vos M, De Vries AM, Dick AD, Juillerat P. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. Journal of Crohn’s and Colitis. 2016;10(3):239 – 54. doi: https://doi.org/10.1093/ecco-jcc/jjv213.

71.

Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B, Afif W. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148(5):1035-58. doi: https://doi.org/10.1053/j.gastro.2015.03.001.

72.

Eliadou E, Day AS, Thompson-Fawcett MW, Gearry RB, Rowbotham DS, Walmsley R, Schultz M, Inns SJ. New Zealand Society of Gastroenterology Guidelines for the management of Refractory Ulcerative Colitis. N Z Med J. 2015;128(1423):63–76. Published 2015 Oct 16.PubMed

73.

Fichera A, Zoccali M. Crohn’s & Colitis Foundation of America, Inc. Guidelines for the surgical treatment of Crohn’s perianal fistulas. Inflamm Bowel Dis. 2015;21(4):753–8. https://doi.org/10.1097/MIB.0000000000000378.CrossRefPubMed

74.

Schwartz DA, Ghazi LJ, Regueiro M, Fichera A, Zoccali M, Ong EM, Mortelé KJ. Guidelines for the multidisciplinary management of Crohn’s perianal fistulas: summary statement. Inflamm Bowel Dis. 2015;21(4):723–30. https://doi.org/10.1097/MIB.0000000000000315.CrossRefPubMed

75.

Strong S, Steele SR, Boutrous M, Bordineau L, Chun J, Stewart DB, Vogel J, Rafferty JF. Clinical practice guideline for the surgical management of Crohn’s disease. Diseases of the Colon & Rectum. 2015;58(11):1021-36. doi: https://doi.org/10.1097/DCR.0000000000000450.

76.

Gecse KB, Bemelman W, Kamm MA, Stoker J, Khanna R, Ng SC, Panés J, Van Assche G, Liu Z, Hart A, Levesque BG. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut. 2014;63(9):1381-92. doi: https://doi.org/10.1136/gutjnl-2013-306709.

77.

Lee J, Allen R, Ashley S, Becker S, Cummins P, Gbadamosi A, Gooding O, Huston J, Le Couteur J, O’Sullivan D, Wilson S. British Dietetic Association evidence-based guidelines for the dietary management of Crohn’s disease in adults. J Hum Nutr Dietetics. 2014;27(3):207–18. https://doi.org/10.1111/jhn.12176.

78.

Ross H, Steele SR, Varma M, Dykes S, Cima R, Buie WD, Rafferty J. Practice parameters for the surgical treatment of ulcerative colitis. Diseases of the colon & rectum. 2014;57(1):5–22. doi: https://doi.org/10.1097/DCR.0000000000000030.

79.

Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J. Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU. Gastroenterologia y hepatologia. 2013;36(2):104 – 14. doi: https://doi.org/10.1016/j.gastrohep.2012.09.006.

80.

Leung WK, Ng SC, Chow DK, Lao WC, Leung VK, Li MK, Hui YT, Ng SS, Hui AJ, Lai ST, Lam JT. Use of biologics for inflammatory bowel disease in Hong Kong: consensus statement. Hong Kong Med J. 2013;19(1):61–8.PubMed

81.

Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck–Ytter YT. American Gastroenterological Association institute guideline on the use of thiopurines, methotrexate, and anti–TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145(6):1459-63. doi: https://doi.org/10.1053/j.gastro.2013.10.047.

82.

Theede K, Dahlerup JF, Fallingborg J, Hvas CL, Kjeldsen J, Munck LK, Nordgaard-Lassen I. Biologic therapy in inflammatory bowel disease. Hepatology. 2013; 60(6): C4652. Available from: https://pubmed.ncbi.nlm.nih.gov/23743116/.

83.

Ueno F, Matsui T, Matsumoto T, Matsuoka K, Watanabe M, Hibi T. Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan. J Gastroenterol. 2013;48(1):31–72. https://doi.org/10.1007/s00535-012-0673-1.

84.

Bitton A, Buie D, Enns R, Feagan BG, Jones JL, Marshall JK, Whittaker S, Griffiths AM, Panaccione R, Canadian Association of Gastroenterology Severe Ulcerative Colitis Consensus Group. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Official journal of the American College of Gastroenterology| ACG. 2012;107(2):179 – 94. doi: https://doi.org/10.1038/ajg.2011.386.

85.

Mowat C, Cole A, Windsor AL, Ahmad T, Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, Lees C. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60(5):571–607. doi: https://doi.org/10.1136/gut.2010.224154.

86.

Orlando A, Armuzzi A, Papi C, Annese V, Ardizzone S, Biancone L, Bortoli A, Castiglione F, D’Incà R, Gionchetti P, Kohn A, Italian Society of Gastroenterology; Italian Group for the study of Inflammatory Bowel Disease. The italian society of Gastroenterology (SIGE) and the Italian Group for the study of inflammatory bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis. 2011;43(1):1–20. https://doi.org/10.1016/j.dld.2010.07.010.CrossRefPubMed

87.

Zambrano-Sánchez R, Alvarez-Mena P, Hidalgo D, Liquitay CM, Franco JV, Vernooij RW, Simancas-Racines D, Viteri-García A, Montesinos-Guevara C. Quality assessment of clinical practice guidelines (CPG) for the diagnosis and treatment of inflammatory bowel disease using the AGREE II instrument: a systematic review. BMC Gastroenterol. 2022;22(1):447. https://doi.org/10.1186/s12876-022-02539-9.CrossRefPubMedPubMedCentral

88.

Wang X, Yang YM, Yang T, An LY, Chen XZ, Qi YX, He HY, Fan HB, Sun DL. Evaluation of pharmacotherapy recommendations in guidelines for inflammatory bowel disease. J Clin Pharm Ther. 2021;46(3):599–609. https://doi.org/10.1111/jcpt.13368.

89.

Xiao BH, Ma XD, Lv JJ, Yang T, Liu XJ, An LY, Qi YX, Lu ML, Duan YQ, Sun DL. Systematic evaluation of the diagnostic approach of inflammatory bowel disease guidelines. Int J Clin Pract. 2021;75(10):e14365. https://doi.org/10.1111/ijcp.14365.

90.

Feuerstein JD, Akbari M, Gifford AE, Cullen G, Leffler DA, Sheth SG, Cheifetz AS. Systematic review: the quality of the scientific evidence and conflicts of interest in international inflammatory bowel disease practice guidelines. Aliment Pharmacol Ther. 2013;37(10):937–46. https://doi.org/10.1111/apt.12290.

91.

Ng JY, Liang L, Gagliardi AR. The quantity and quality of complementary and alternative medicine clinical practice guidelines on herbal medicines, acupuncture and spinal manipulation: systematic review and assessment using AGREE II. BMC complementary and alternative medicine. 2016;16(1):1–0. doi: https://doi.org/10.1186/s12906-016-1410-8.

92.

Ng JY, Azizudin AM. Rheumatoid arthritis and osteoarthritis clinical practice guidelines provide few complementary and alternative medicine therapy recommendations: a systematic review. Clin Rheumatol. 2020;39(10):2861–73. https://doi.org/10.1007/s10067-020-05054-y.

93.

Ng JY, Thakar H. Complementary and alternative medicine mention and recommendations are lacking in colon cancer clinical practice guidelines: a systematic review. Advances in Integrative Medicine. 2021;8(1):3–8. doi: https://doi.org/10.1016/j.aimed.2020.06.002.

94.

Ng JY, Kishimoto V. Multiple sclerosis clinical practice guidelines provide few complementary and alternative medicine recommendations: a systematic review. Complement Ther Med 2021;56:102595. doi: https://doi.org/10.1016/j.ctim.2020.102595.

95.

Ng JY, Jain A. Complementary and alternative medicine mention and recommendations in guidelines for anxiety: a systematic review and quality assessment. Psychiatry Res 2022:114388. doi: https://doi.org/10.1016/j.psychres.2022.114388.

96.

Ng JY, Nazir Z, Nault H. Complementary and alternative medicine recommendations for depression: a systematic review and assessment of clinical practice guidelines. BMC Complement Med Ther. 2020;20(1):1–15. https://doi.org/10.1186/s12906-020-03085-1.CrossRef

97.

Veziari Y, Leach MJ, Kumar S. Barriers to the conduct and application of research in complementary and alternative medicine: a systematic review. BMC Complement Altern Med. 2017;17(1):1–4. https://doi.org/10.1186/s12906-017-1660-0.

98.

Middleton JC, Kalogeropoulos C, Middleton JA, Drapeau M. Assessing the methodological quality of the Canadian Psychiatric Association’s anxiety and depression clinical practice guidelines. J evaluation Clin Pract 2019;25(4):613–21. doi: https://doi.org/10.1111/jep.13026.

99.

Leech BG. The Development of a Clinical Practice Guideline for the Management of Increased Intestinal Permeability. Dissertation. University of Technology Sydney; 2022. https://opus.lib.uts.edu.au/handle/10453/168911.

100.

Grol R, Dalhuijsen J, Thomas S, Veld C, Rutten G, Mokkink H. Attributes of clinical guidelines that influence use of guidelines in general practice: observational study. BMJ. 1998;317(7162):858–61. https://doi.org/10.1136/bmj.317.7162.858.CrossRefPubMedPubMedCentral

101.

Gagliardi AR, Brouwers MC, Palda VA, Lemieux-Charles L, Grimshaw JM. How can we improve guideline use? A conceptual framework of implementability. Implement Sci. 2011;6(1):1–1. https://doi.org/10.1186/1748-5908-6-26.

102.

Légaré F, van der Boivin A, Pakenham C, Burgers J, Légaré J, St-Jacques S, Gagnon S. Patient and public involvement in clinical practice guidelines: a knowledge synthesis of existing programs. Med Decis Making. 2011;31(6):E45–74. https://doi.org/10.1177/0272989X11424401.

103.

Wiercioch W, Akl EA, Santesso N, Zhang Y, Morgan RL, Yepes-Nuñez JJ, Kowalski S, Baldeh T, Mustafa RA, Laisaar KT, Raid U. Assessing the process and outcome of the development of practice guidelines and recommendations: PANELVIEW instrument development. CMAJ 2020;192(40):E1138–45. doi: https://doi.org/10.1503/cmaj.200193.

104.

GRADEpro GD. GRADEpro guideline development tool [software]. McMaster Univ. 2015;435.

105.

Brouwers MC, Spithoff K, Kerkvliet K, Alonso-Coello P, Burgers J, Cluzeau F, Férvers B, Graham I, Grimshaw J, Hanna S, Kastner M. Development and validation of a tool to assess the quality of clinical practice guideline recommendations. JAMA Network Open. 2020;3(5):e205535. doi: https://doi.org/10.1001/jamanetworkopen.2020.5535.

Title: Complementary and alternative medicine mention and recommendations in inflammatory bowel disease guidelines: systematic review and assessment using AGREE II
Authors: Jeremy Y. Ng
Henry Liu
Michelle Chenghuazou Wang
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Chronic Inflammatory Bowel Disease
Crohn's Disease
Ulcerative Colitis
Probiotics
Published in: BMC Complementary Medicine and Therapies / Issue 1/2023
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-023-04062-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Complementary and alternative medicine mention and recommendations in inflammatory bowel disease guidelines: systematic review and assessment using AGREE II

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Efficacy and safety of topical 0.1% cannabidiol for managing recurrent aphthous ulcers: a randomized controlled trial

Penthorum chinense Pursh improves type 2 diabetes mellitus via modulating gut microbiota in db/db mice

Tianhuang formula regulates adipocyte mitochondrial function by AMPK/MICU1 pathway in HFD/STZ-induced T2DM mice

Protocatechuic aldehyde acts synergistically with dacarbazine to augment DNA double-strand breaks and promote apoptosis in cutaneous melanoma cells

Potential mechanisms of osthole against bladder cancer cells based on network pharmacology, molecular docking, and experimental validation

Six Spain Thymus essential oils composition analysis and their in vitro and in silico study against Streptococcus mutans